Compare HBT & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HBT | LBRX |
|---|---|---|
| Founded | 1920 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.5B |
| IPO Year | 2019 | 2025 |
| Metric | HBT | LBRX |
|---|---|---|
| Price | $35.68 | $48.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $30.75 | ★ $46.60 |
| AVG Volume (30 Days) | 129.7K | ★ 363.8K |
| Earning Date | 04-27-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.29% | N/A |
| EPS Growth | 7.96 | ★ 98.22 |
| EPS | ★ 1.12 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $35.73 | N/A |
| Revenue Next Year | $7.01 | N/A |
| P/E Ratio | $32.08 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.36 | $13.40 |
| 52 Week High | $37.51 | $49.97 |
| Indicator | HBT | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | 58.06 | 67.95 |
| Support Level | $35.34 | $22.85 |
| Resistance Level | $37.17 | $49.14 |
| Average True Range (ATR) | 0.73 | 2.51 |
| MACD | -0.25 | -0.15 |
| Stochastic Oscillator | 41.90 | 85.38 |
HBT Financial Inc provides a comprehensive suite of business, commercial, wealth management, and retail banking products and services to individuals, businesses, and municipal entities throughout Central and Northeastern Illinois and Eastern Iowa. It operates through one reportable segment: community banking. It generates revenue from Card income, Wealth management fees, and Service charges on deposit accounts.
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.